These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The quest to overcome resistance to EGFR-targeted therapies in cancer. Chong CR; Jänne PA Nat Med; 2013 Nov; 19(11):1389-400. PubMed ID: 24202392 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Dhomen NS; Mariadason J; Tebbutt N; Scott AM Crit Rev Oncog; 2012; 17(1):31-50. PubMed ID: 22471663 [TBL] [Abstract][Full Text] [Related]
4. Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. Lee S; Rauch J; Kolch W Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046099 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Wykosky J; Fenton T; Furnari F; Cavenee WK Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840 [TBL] [Abstract][Full Text] [Related]
6. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy. Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280 [TBL] [Abstract][Full Text] [Related]
7. HER family in cancer progression: From discovery to 2020 and beyond. Kumar R; George B; Campbell MR; Verma N; Paul AM; Melo-Alvim C; Ribeiro L; Pillai MR; da Costa LM; Moasser MM Adv Cancer Res; 2020; 147():109-160. PubMed ID: 32593399 [TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. Pines G; Köstler WJ; Yarden Y FEBS Lett; 2010 Jun; 584(12):2699-706. PubMed ID: 20388509 [TBL] [Abstract][Full Text] [Related]
9. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Arteaga CL; Engelman JA Cancer Cell; 2014 Mar; 25(3):282-303. PubMed ID: 24651011 [TBL] [Abstract][Full Text] [Related]
10. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. Yamaoka T; Ohba M; Ohmori T Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29140271 [TBL] [Abstract][Full Text] [Related]
11. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review. Najafi M; Ahmadi A; Mortezaee K Cell Biol Int; 2019 Nov; 43(11):1206-1222. PubMed ID: 31136035 [TBL] [Abstract][Full Text] [Related]
12. Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway. Weickhardt AJ; Tebbutt NC; Mariadason JM Curr Cancer Drug Targets; 2010 Dec; 10(8):824-33. PubMed ID: 20718704 [TBL] [Abstract][Full Text] [Related]
13. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism? Lv J; Wang J; Chang S; Liu M; Pang X Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443 [TBL] [Abstract][Full Text] [Related]
14. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Van Emburgh BO; Sartore-Bianchi A; Di Nicolantonio F; Siena S; Bardelli A Mol Oncol; 2014 Sep; 8(6):1084-94. PubMed ID: 24913799 [TBL] [Abstract][Full Text] [Related]
16. Drugging the addict: non-oncogene addiction as a target for cancer therapy. Nagel R; Semenova EA; Berns A EMBO Rep; 2016 Nov; 17(11):1516-1531. PubMed ID: 27702988 [TBL] [Abstract][Full Text] [Related]
17. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B. Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903 [TBL] [Abstract][Full Text] [Related]
18. Cancer therapy based on oncogene addiction. McCormick F J Surg Oncol; 2011 May; 103(6):464-7. PubMed ID: 21480237 [TBL] [Abstract][Full Text] [Related]
19. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation. Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489 [TBL] [Abstract][Full Text] [Related]
20. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Bertotti A; Burbridge MF; Gastaldi S; Galimi F; Torti D; Medico E; Giordano S; Corso S; Rolland-Valognes G; Lockhart BP; Hickman JA; Comoglio PM; Trusolino L Sci Signal; 2009; 2(102):er11. PubMed ID: 20039471 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]